English 
Spanish 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 开放获取期刊获得更多读者和引用
700 种期刊 和 15,000,000 名读者 每份期刊 获得 25,000 多名读者
抽象的
Final Efficacy Results of a Randomized Phase II Study of Recombinant Interleukin-21 Compared to Decarbonize in Patients with Recurrent or Metastatic Melanoma
Dr.Teresa M. Petrella
Interleukin-21(IL-21) is a T-cell derived cytokine with antitumour activity
dependent on NK cells or CD8+ T cells. A previous phase II study demonstrated
an overall response rate (ORR) of 22.5% in previously untreated patients with
metastatic melanoma. We conducted a multi-centre randomized phase II study in
metastatic melanoma patients to evaluate the efficacy, toxicity, immunogenicity
and biomarkers associated with response to IL-21 versus dacarbazine (DTIC).
免责声明: 此摘要通过人工智能工具翻译，尚未经过审核或验证。